![Joseph Manhede](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 179 810 $ al 30/06/2026
Joseph Manhede is Chief Accounting Officer at Rocket Pharmaceuticals, Inc. since 2026.
Formerly, Mr. Manhede was Vice President & Financial Controller at Outlook Therapeutics, Inc. Mr. Manhede earned an MBA from Holy Family University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 08/07/2026 | 52.576 ( 0,05 % ) | 179 810 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01/04/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Holy Family University
 Holy Family University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Outlook Therapeutics, Inc.
 Outlook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bevacizumab therapeutic products | Health Technology |
Rocket Pharmaceuticals, Inc.
 Rocket Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
